HDL Dysfunction During the Acute Stage of Stroke (RUSH)

Centre Hospitalier Universitaire de la Réunion

Status: Unknown

Conditions: Stroke, Acute

Treatments: Other: Haemorrhagic stroke; Other: Ischemic stroke

Study type: Observational

Funder types: Other

Identifiers

NCT03245957

2016/CHU/06

Details and patient eligibility

About

The study investigates the effect of plasma myeloperoxidase (MPO) concentrations on HDL dysfunction during the acute stage of ischemic and haemorrhagic strokes.

Full description

MRI or CT scan are used to confirm the diagnosis of haemorrhagic, ischemic and mimick stroke.

Plasma anf HDL-MPO concentrations, as well as potent HDL dysfunction, are compared in the 3 cases.

The investigators hypothesis is that MPO concentrations and subsequent HDL dysfunction could be higher in ischemic strokes than in haemorrhagic ones. MPO could be a examined as a potent marker of early stage of ischemic stroke.

Plasma MPO levels could also be discriminant regarding the mimick strokes in patient exhibiting stroke clinical picture.

Enrollment: 112 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Patients with less than 12 hours stroke clinical signs:

• hemiparesis or hemiplegia
• unilateral sensitivity disorder
• language impairment
• balance disorder
• dizziness, bilateral or monocular vision totally or partially lost

Exclusion criteria

• Pregnancy
• head trauma since the last 3 months
• stroke since the last 3 months
• myocardial infarction since the last 3 months
• patient disagrees to be enrolled in the study

Trial design

112 participants in 3 patient groups

Ischemic stroke

Description:

Patients with ischemic stroke diagnosed by MRI or CT scan

Treatment:

Other: Ischemic stroke

Haemorrhagic stroke

Description:

Patients without haemorrhagic stroke diagnosed by MRI or CT scan

Treatment:

Other: Haemorrhagic stroke

Mimick stroke

Description:

Patients without haemorrhagic or ischemic stroke diagnosed by MRI or CT scan